Rigel Pharmaceuticals (RIGL) Receivables - Net (2016 - 2025)
Rigel Pharmaceuticals has reported Receivables - Net over the past 12 years, most recently at $51.8 million for Q4 2025.
- For Q4 2025, Receivables - Net rose 24.39% year-over-year to $51.8 million; the TTM value through Dec 2025 reached $51.8 million, up 24.39%, while the annual FY2025 figure was $51.8 million, 24.39% up from the prior year.
- Receivables - Net for Q4 2025 was $51.8 million at Rigel Pharmaceuticals, up from $45.9 million in the prior quarter.
- Over five years, Receivables - Net peaked at $142.2 million in Q1 2021 and troughed at $3.0 million in Q1 2025.
- A 5-year average of $31.6 million and a median of $25.5 million in 2023 define the central range for Receivables - Net.
- Biggest five-year swings in Receivables - Net: surged 1372.0% in 2021 and later tumbled 89.28% in 2022.
- Year by year, Receivables - Net stood at $15.5 million in 2021, then increased by 29.27% to $20.0 million in 2022, then soared by 52.75% to $30.6 million in 2023, then surged by 36.22% to $41.6 million in 2024, then rose by 24.39% to $51.8 million in 2025.
- Business Quant data shows Receivables - Net for RIGL at $51.8 million in Q4 2025, $45.9 million in Q3 2025, and $39.9 million in Q2 2025.